BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells.

Sci Rep · 2018 · PMC6279795 · PMID 30514852

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference in survival did not reach statistical significance, BST-2 + IBC-bearing patients had a median overall survival (OS) time of 7 years and an AUC of 914.8, while BST-2 − IBC-bearing patients had an OS of 15 years and an AUC of 1,260 (Fig. 1D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.